Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The bisphosphonate alendronate is now widely used for the treatment of postmenopausal osteoporosis and has recently been approved for its prevention. Like many drugs, the mechanisms underlying alendronate's therapeutic effect are not well understood. Alendronate treatment at a dose of 10 mg/day results in a 5% increase in spinal bone mineral density (BMD) over the first year.1 BMD continues to increase, albeit at a slower rate, at this site during the second and third years of treatment. The magnitude and duration of the increase in BMD has led to speculation that alendronate is doing more than simply reducing remodeling space and that it may possess anabolic activity. Verification of this awaits the detailed results from histomorphometric analysis of bone biopsies taken before and after treatment. In the meantime, in an interesting paper that appears in this issue of JBMR, Heaney and colleagues2 have performed a theoretical investigation of the mode of action of alendronate by applying data from the study of Liberman et al.1 to a computer simulation of bone remodeling.3 Using this model, an excellent fit to the observed clinical data was obtained by simulating a 36–38% reduction in remodeling activation frequency, coupled with a positive balance in each remodeling unit of 1.1–1.4%. By dint of closing down the remodeling space, the reduction in activation frequency accounts for the early and rapid increase in BMD, while the positive bone balance accounts for the continued, although smaller, gain in BMD observed in the second and third year of therapy. The model does not attempt to elucidate the structural or cellular basis for the positive bone balance at the level of the remodeling unit. A positive balance can be achieved either by reducing the depth of the resorption cavity without a decrease in the amount of bone deposited or by increasing the amount of bone deposited, leading to an increase in the thickness of the trabecular packet or, of course, by a combination of the two. The bisphosphonate etidronate reduced resorption depth in human iliac trabecular bone by almost 30% after 1 year of treatment,4 but no such data are yet available for alendronate. Etidronate did not change the thickness of trabecular packets, but recent studies in osteoporotic women suggest that this is increased after 2 years of alendronate treatment at 10 and 20 mg/day. This result was not confirmed, however, after 3 years of treatment (P.J. Meunier, personal communication). A direct stimulatory effect of alendronate on bone formation in vivo is quite possible in view of the fact that it has been shown to increase the proliferation and functional activity (including matrix protein synthesis and mineralization) of cartilage and bone cells in vitro.5-9 Regardless of the underlying cellular mechanism(s), an increase in trabecular thickness, implying a positive bone balance at the level of the remodeling unit, has been reported in ovariectomized baboons treated with alendronate10 and in humans treated with etidronate.11 It is well recognized that improvements in bone mass do not necessarily lead to increased resistance to fracture, e.g., sodium fluoride therapy.12, 13 Conversely, in the case of alendronate, it has recently been argued that the degree of vertebral fracture protection achieved is approximately 2-fold greater than would be predicted from the magnitude of the increase in bone mass.14 Similar analysis for other antiresorptive agents (calcitonin, etidronate, and estrogen) showed actual reductions in fracture risk which were substantially higher than would be expected on the basis of the BMD changes alone. This implies that the treatment confers additional benefit(s) over that gained from the increase in bone mass alone. One such benefit is likely to be due to the reduction in bone turnover since high bone turnover has been shown in other studies to be an independent risk factor for fracture.15 There are at least three plausible explanations for why a decrease in turnover rate might improve the mechanical competence of the skeleton in addition to reduction of the remodeling space. First, it will reduce the probability of trabecular plate perforation. Second, each trabecular element will have fewer resorption lacunae and will be less prone to buckling and failure. This applies particularly to vertical trabeculae in the vertebrae, which, in osteoporotic individuals, are frequently no longer buttressed by horizontal trabeculae.16 Third, a prolongation of the formation period of the bone remodeling cycle, may be associated with the reduced activation frequency, a factor that was considered in Heaney et al.'s model.2 This could have the benefit of allowing a greater amount of bone mineral to be incorporated into the organic matrix. In fact, this apparently occurs in ovariectomized baboons treated with alendronate in which the bone matrix has been shown to be more highly mineralized using the technique of quantitative microradiogr
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396
Heaney, R. P. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091003 · Cited by 286 · cited 1×
“to a computer simulation of bone remodeling.((3)) Using this model, an excellent fit to the observed clinical data was obtained by simulating a 36–38% reduction in remodeling activation frequency, coupled with a positive balance in each remodeling unit of 1.”
Method
Cited by
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
Langdahl, B., Ferrari, S., & Dempster, D. W. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16670154 · Cited by 432
Self-citationHochberg, M. C., Ross, P. D., Black, D., Cummings, S. R., Genant, H. K., Nevitt, M. C., Barrett-Connor, E., Musliner, T., Thompson, D., & for the Fracture Intervention Trial Research Group (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1246::aid-anr22>3.0.co;2-u · Cited by 287
Neumann, T., Oelzner, P., Petrow, P. K., Thoss, K., Hein, G., Stein, G., & Bräuer, R. (2006) · Inflammation Research · doi:10.1007/s00011-005-0005-5 · Cited by 12
“There is some evidence that bisphosphonates directly increase osteoblast activity and inhibit apoptosis [43].”
Background
Metadata
- Authors
- Dempster, D. W.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-08-01
- Volume
- 12
- Issue
- 8
- Pages
- 1152-1154
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1982091806
- Cited by
- 40
- References
- 2
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis. https://app.cochat.ai/papers/10.1359/jbmr.1997.12.8.1152
- The paper
- Dempster, D. W. (1997). Exploiting and Bypassing the Bone Remodeling Cycle to Optimize the Treatment of Osteoporosis. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.1997.12.8.1152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.